Piramal Pharma Charts Bold Sustainability Path In FY2025 Report, Targets Zero Waste And Emission Cuts

Piramal Pharma Ltd (PPL) has released its FY2025 Sustainability Report under the theme Innovating Responsibly. Growing Sustainably., showcasing a year of measurable progress across environmental, social, and governance pillars. The report outlines the company’s decarbonization glidepath, operational milestones, and stakeholder-centric initiatives, reinforcing its commitment to long-term value creation through science-led innovation and ethical business practices.

 

Key Highlights From The FY2025 Report

 

•⁠  ⁠Achieved a 6 percent year-on-year reduction in Scope 1 and Scope 2 greenhouse gas emissions  

•⁠  ⁠Increased renewable energy usage by 7.8 percent, with 20.2 percent of total energy sourced from bioenergy  

•⁠  ⁠Attained zero hazardous waste to landfill and set a target to recycle 90 percent of non-hazardous waste  

•⁠  ⁠Saved 2.10 lakh kilolitres of freshwater through integrated water stewardship programs  

•⁠  ⁠Converted coal-fired steam boilers at the Digwal facility to renewable biomass briquettes  

 

Responsible Operations And Climate Action

 

•⁠  ⁠PPL’s decarbonization strategy includes transitioning to energy-efficient technologies and expanding renewable energy adoption across sites  

•⁠  ⁠Biodiversity initiatives involved planting over 2,000 saplings and maintaining 30 percent green cover at Indian facilities  

•⁠  ⁠Waste segregation and circularity programs were scaled to reduce landfill dependency and promote reuse  

•⁠  ⁠The company’s water conservation efforts focused on rainwater harvesting, recycling, and process optimization  

 

Business Resilience And Governance

 

•⁠  ⁠PPL maintained 100 percent compliance with its Code of Conduct training across global operations  

•⁠  ⁠The Board composition included 50 percent independent directors and 30 percent women representation, exceeding statutory norms  

•⁠  ⁠Conducted structured risk assessments and policy development to embed ethical practices and enhance transparency  

•⁠  ⁠Assessed 26.5 percent of critical suppliers on sustainability criteria, with capacity-building plans for 30 percent by FY2026  

 

Quality, Excellence, And Regulatory Performance

 

•⁠  ⁠Completed 36 successful regulatory inspections, including two by the USFDA  

•⁠  ⁠Executed 165 customer audits globally, reinforcing trust and compliance across markets  

•⁠  ⁠Continued digital transformation through Catalyst NxGen (S/4HANA), deploying 17 governance dashboards for operational agility  

•⁠  ⁠Achieved customer satisfaction scores of 85 percent in CDMO/PPS and 87 percent in Critical Care/PCC segments  

 

Stakeholder Centricity And Social Impact

 

•⁠  ⁠Community development programs focused on education, skill-building, and health initiatives at manufacturing sites  

•⁠  ⁠Human capital management included safety training, diversity programs, and employee engagement platforms  

•⁠  ⁠PPL’s sustainability strategy aligns with multiple United Nations Sustainable Development Goals, ensuring global relevance  

•⁠  ⁠The company’s efforts were externally assured by DNV, adding credibility to its disclosures and performance metrics  

 

Reporting Framework And Assurance

 

•⁠  ⁠The FY2025 report was prepared in accordance with the Global Reporting Initiative Universal Standards 2021  

•⁠  ⁠It incorporates all nine disclosure requirements under GRI 1, GRI 2, and GRI 3, ensuring comprehensive coverage of material topics  

•⁠  ⁠The report includes a GHG verification statement and assurance declaration, reinforcing data integrity and transparency  

 

Conclusion

 

Piramal Pharma’s FY2025 Sustainability Report reflects a deepened commitment to responsible growth, operational excellence, and stakeholder engagement. With clear targets for decarbonization, waste reduction, and ethical governance, the company is positioning itself as a global leader in sustainable pharmaceutical practices. As it continues to embed ESG principles across its value chain, PPL’s journey offers a blueprint for resilience and innovation in a rapidly evolving industry.

 

Sources: Piramal Pharma FY2025 Sustainability Report, Futunn Newswire, Piramal Pharma Sustainability Portal.